[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635743":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":47,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Allogeneic WTX-212C","EXPERIMENTAL","Participants will receive allogeneic WTX-212C via intravenous infusion in dose-escalation and dose-expansion cohorts.",[13],"Drug: allogeneic WTX-212C",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","allogeneic WTX-212C","allogeneic WTX-212C is an investigational allogeneic engineered red blood cell-based injectable product administered intravenously.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Yang Liu, PhD","CONTACT","8613666601475","Yangliuqq2003@163.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":20,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Zhejiang Provincial Hospital","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":36,"coordinates":37},"Point",[38,39],120.16142,30.29365,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Liu Yang","Principal Investigator",[48,51],{"name":49,"class":50},"Westlake Therapeutics","INDUSTRY",{"name":52,"class":6},"First People's Hospital of Hangzhou","100635743","early-phase-1-allogeneic-wtx-212c-in-advanced-solid-tumors-100635743",false,"NCT07556653","Allogeneic WTX-212C in Advanced Solid Tumors","A Multicenter, Open-label, Single-arm Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Allogeneic WTX-212C Engineered Red Blood Cell Injection in Patients With Advanced Solid Tumors","WTX-212C-IIT","Inclusion Criteria:\n\n* Age 18-75 years\n* Histologically or cytologically confirmed advanced solid tumors\n* At least one measurable lesion per RECIST 1.1\n* ECOG performance status ≤1\n* Adequate organ function\n* Life expectancy ≥12 weeks\n\nExclusion Criteria:\n\n* Uncontrolled serious medical conditions\n* Active or uncontrolled infections\n* Symptomatic or unstable CNS metastases\n* History of severe hypersensitivity to biologic agents\n* Autoimmune diseases requiring systemic treatment\n* Prior severe immune-related adverse events\n* Conditions affecting red blood cell integrity","ALL","18 Years","75 Years",{"count":65,"type":66},24,"ESTIMATED","INTERVENTIONAL",[69],"EARLY_PHASE1","This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options.\n\nThe study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.",[72],"Advanced Solid Tumors",[74,75,76,77,78,79],"Engineered Red Blood Cells","Immunotherapy","Phase I","Solid Tumor","Allogeneic Engineered Red Blood Cell","uRBC","2026-07-12",{"date":82,"type":83},"2026-07-14","ACTUAL",{"date":85,"type":83},"2026-06-26",{"date":87,"type":66},"2028-04-09",{"name":5,"class":6},1]